Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score
Top Cited Papers
Open Access
- 21 March 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 14 (3) , e1002258
Abstract
Identifying individuals at risk for developing Alzheimer disease (AD) is of utmost importance. Although genetic studies have identified AD-associated SNPs in APOE and other genes, genetic information has not been integrated into an epidemiological framework for risk prediction. Using genotype data from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer’s Project (IGAP Stage 1), we identified AD-associated SNPs (at p < 10−5). We then integrated these AD-associated SNPs into a Cox proportional hazard model using genotype data from a subset of 6,409 AD patients and 9,386 older controls from Phase 1 of the Alzheimer’s Disease Genetics Consortium (ADGC), providing a polygenic hazard score (PHS) for each participant. By combining population-based incidence rates and the genotype-derived PHS for each individual, we derived estimates of instantaneous risk for developing AD, based on genotype and age, and tested replication in multiple independent cohorts (ADGC Phase 2, National Institute on Aging Alzheimer’s Disease Center [NIA ADC], and Alzheimer’s Disease Neuroimaging Initiative [ADNI], total n = 20,680). Within the ADGC Phase 1 cohort, individuals in the highest PHS quartile developed AD at a considerably lower age and had the highest yearly AD incidence rate. Among APOE ε3/3 individuals, the PHS modified expected age of AD onset by more than 10 y between the lowest and highest deciles (hazard ratio 3.34, 95% CI 2.62–4.24, p = 1.0 × 10−22). In independent cohorts, the PHS strongly predicted empirical age of AD onset (ADGC Phase 2, r = 0.90, p = 1.1 × 10−26) and longitudinal progression from normal aging to AD (NIA ADC, Cochran–Armitage trend test, p = 1.5 × 10−10), and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 × 10−6, and Consortium to Establish a Registry for Alzheimer’s Disease score for neuritic plaques, p = 6.8 × 10−6) and in vivo markers of AD neurodegeneration (ADNI, volume loss within the entorhinal cortex, p = 6.3 × 10−6, and hippocampus, p = 7.9 × 10−5). Additional prospective validation of these results in non-US, non-white, and prospective community-based cohorts is necessary before clinical use. We have developed a PHS for quantifying individual differences in age-specific genetic risk for AD. Within the cohorts studied here, polygenic architecture plays an important role in modifying AD risk beyond APOE. With thorough validation, quantification of inherited genetic variation may prove useful for stratifying AD risk and as an enrichment strategy in therapeutic trials.Keywords
All Related Versions
Funding Information
- National Institutes of Health (NIH-AG046374)
- National Institutes of Health (K01AG049152)
- National Institutes of Health (R01MH100351)
- National Alzheimer's Coordinating Center
- Radiological Society of North America
- Foundation of the American Society of Neuroradiology
- Norges Forskningsråd ((#213837, #225989, #223273, #237250/EU JPND)
- South East Norway Health Authority (2013-123)
- Norske Kvinners Sanitetsforening
- KG Jebsen Foundation
This publication has 30 references indexed in Scilit:
- Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E ϵ4, and the Risk of Late-Onset Alzheimer Disease in African AmericansJAMA, 2013
- Power and Predictive Accuracy of Polygenic Risk ScoresPLOS Genetics, 2013
- Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traitsNature Genetics, 2012
- Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's diseaseNature Genetics, 2011
- Prediction of individual genetic risk to disease from genome-wide association studiesGenome Research, 2007
- The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data SetAlzheimer Disease & Associated Disorders, 2007
- Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.American Journal of Public Health, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)Neurology, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984